1
|
Forest F, Dal Col P, Laville D, Court A, Rillardon M, Ramirez C, Rivoirard R, Stephan JL, Vassal F, Péoc'h M. Cyclin D1 expression in ganglioglioma, pleomorphic xanthoastrocytoma and pilocytic astrocytoma. Exp Mol Pathol 2021; 121:104652. [PMID: 34022185 DOI: 10.1016/j.yexmp.2021.104652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Revised: 05/11/2021] [Accepted: 05/17/2021] [Indexed: 11/18/2022]
Abstract
Ganglioglioma, pleomorphic xanthoastrocytoma (PXA) and pilocytic astrocytoma are rare brain neoplasms with frequent activation of mitogen-activated protein (MAP) kinase pathway. A downstream marker of MAP-kinase pathway activation is cyclin D1. However, the expression of cyclin D1 has not been studied in the differential diagnosis between these brain tumors. The aim of this work is to compare the expression of cyclin D1 in ganglioglioma, PXA, pilocytic astrocytoma. We also compared cyclin D1 expression in giant cell glioblastoma and in IDH wild type glioblastoma. Our work shows that roughly half of gangliogliomas have ganglion cells stained by cyclin D1 while two third of PXA have pleormophic cells stained by cyclin D1 and 15% of giant cell glioblastoma have pleomorphic cells stained by cyclin D1 (p < 0.001). Cyclin D1 never stains normal neurons either in the adjacent cortex of circumscribed tumor, or in entrapped neurons in IDH wild type glioblastomas. The expression of cyclin D1 is correlated to the presence of BRAF V600E mutation in ganglioglioma and PXA (p = 0.002). To conclude, cyclin D1 positivity might be used to confirm the neoplastic nature of ganglion cells. Cyclin D1 is expressed in most cases of BRAF V600E mutated gangliogliomas but also in cases without BRAF mutations suggesting an activation of MAP-kinase pathway through another way. Cyclin D1 immunohistochemistry has currently no or little role in the differential diagnosis of pilocytic astrocytoma. Its role in the differential diagnosis between PXA and giant cell glioblastoma needs to be further investigated on external series.
Collapse
Affiliation(s)
- Fabien Forest
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France; University Hospital of Saint Etienne, North Hospital, Department of Molecular Biology of Tumors, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France; Corneal Graft Biology, Engineering and Imaging Laboratory, BiiGC, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France.
| | - Pierre Dal Col
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - David Laville
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Alice Court
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Maxime Rillardon
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Carole Ramirez
- University Hospital of Saint Etienne, North Hospital, Department of Neurology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France; Lucien Neuwith Cancer Institute, Department of Medical Oncology, Avenue Albert Raimond, 108 bis Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez, France
| | - Romain Rivoirard
- Lucien Neuwith Cancer Institute, Department of Medical Oncology, Avenue Albert Raimond, 108 bis Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez, France
| | - Jean-Louis Stephan
- University Hospital of Saint Etienne, North Hospital, Department of Pediatric Oncology, Avenue Albert Raimond. 42055, Saint Etienne CEDEX 2, France
| | - François Vassal
- University Hospital of Saint Etienne, North Hospital, Department of Neurosurgery, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France
| | - Michel Péoc'h
- University Hospital of Saint Etienne, North Hospital, Department of Pathology, Avenue Albert Raimond, 42055, Saint Etienne CEDEX 2, France; Corneal Graft Biology, Engineering and Imaging Laboratory, BiiGC, EA2521, Federative Institute of Research in Sciences and Health Engineering, Faculty of Medicine, Jean Monnet University, Saint-Etienne, France
| |
Collapse
|
2
|
Bret D, Chappuis V, Poncet D, Ducray F, Silva K, Mion F, Vasiljevic A, Ferraro-Peyret C, Mottolese C, Leblond P, Gabut M, Frappaz D, Streichenberger N, Meyronet D, Bringuier PP, Barritault M. A Multiplex Quantitative Reverse Transcription Polymerase Chain Reaction Assay for the Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pilocytic Astrocytomas. Mol Diagn Ther 2019; 23:537-545. [PMID: 31087282 DOI: 10.1007/s40291-019-00403-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND AND OBJECTIVE Genomic duplications and fusion involving BRAF and KIAA1549 that create fusion proteins with constitutive B-RAF kinase activity are a hallmark of pilocytic astrocytomas (PAs). The detection of KIAA1549-BRAF fusion transcripts is of paramount importance to classify these tumors and to identify patients who could benefit from BRAF inhibitors. In a clinical setting, the available material for molecular analysis from these pediatric tumors is often limited to formalin-fixed paraffin-embedded (FFPE) tissue. The aim of the present study was to develop a new method to detect the three most frequent KIAA1549-BRAF fusion transcripts, 15-9, 16-11, and 16-9, where numbers refer to the exons fused together, using a FFPE-compatible multiplex quantitative reverse transcription polymerase chain reaction (qRT-PCR). METHODS We compared performance of the assay to a reference singleplex method on a collection of 46 FFPE PAs. RESULTS The results showed that both methods are comparable. The multiplex method had an overall 97% sensitivity and 100% specificity compared to the singleplex method, and agreement between the two techniques was almost perfect (Cohen's kappa: 0.97). There was no evidence of a significant difference between the qRT-PCR efficiencies of the multiplex technique and of the singleplex assay for all fusion transcripts and for GAPDH, the latter used as a reference gene. The multiplex method consumed four times less complementary DNA (cDNA), cost less, and required half the hands-on technical time. CONCLUSION The results show that it could be beneficial to implement the multiplex method in a clinical setting, where samples presenting low quantity of degraded RNA are not unusual.
Collapse
Affiliation(s)
- David Bret
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Valentin Chappuis
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Delphine Poncet
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - François Ducray
- University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Service de Neuro-oncologie, Hospices Civils de Lyon, Hôpital Neurologique, Lyon, France.,Transcriptome Diversity in Stem Cells Laboratory, Cancer Cell Plasticity Department, Cancer Research Centre of Lyon, INSERM U1052, CNRS, UMR 5286, Lyon, France
| | - Karen Silva
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France
| | - Fabrice Mion
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France
| | - Alexandre Vasiljevic
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Carole Ferraro-Peyret
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Carmine Mottolese
- Service de Neurochirurgie Lyon, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France
| | - Pierre Leblond
- Service d'Oncologie, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
| | - Mathieu Gabut
- Transcriptome Diversity in Stem Cells Laboratory, Cancer Cell Plasticity Department, Cancer Research Centre of Lyon, INSERM U1052, CNRS, UMR 5286, Lyon, France
| | - Didier Frappaz
- Service d'Oncologie, Institut d'Hématologie et d'Oncologie Pédiatrique, Lyon, France
| | - Nathalie Streichenberger
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - David Meyronet
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.,Transcriptome Diversity in Stem Cells Laboratory, Cancer Cell Plasticity Department, Cancer Research Centre of Lyon, INSERM U1052, CNRS, UMR 5286, Lyon, France
| | - Pierre-Paul Bringuier
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France.,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Marc Barritault
- Service de Cytologie et d'Anatomie Pathologique, Département de Biopathologie Moléculaire et de Département de Neuropathologie, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France. .,University of Lyon, Université Claude Bernard Lyon 1, Lyon, France. .,Transcriptome Diversity in Stem Cells Laboratory, Cancer Cell Plasticity Department, Cancer Research Centre of Lyon, INSERM U1052, CNRS, UMR 5286, Lyon, France.
| |
Collapse
|
4
|
Gatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Faivre J, Bossard N, Uhry Z, Colonna M, Clavel J, Lacour B, Desandes E, Brenner H, Kaatsch P, Katalinic A, Garami M, Jakab Z, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Barchielli A, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Capocaccia R, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Zucchetto A, De Angelis R, Caldora M, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Filiberti R, Marani E, Ricci P, Pascucci C, Autelitano M, Spagnoli G, Cirilli C, Fusco M, Vitale M, Usala M, Vitale F, Ravazzolo B, Michiara M, Merletti F, Maule M, Tumino R, Mangone L, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, et alGatta G, Peris-Bonet R, Visser O, Stiller C, Marcos-Gragera R, Sánchez MJ, Lacour B, Kaatsch P, Berrino F, Rutkowski S, Botta L, Hackl M, Zielonke N, Oberaigner W, Van Eycken E, Henau K, Valerianova Z, Dimitrova N, Sekerija M, Storm H, Engholm G, Mägi M, Aareleid T, Malila N, Seppä K, Faivre J, Bossard N, Uhry Z, Colonna M, Clavel J, Lacour B, Desandes E, Brenner H, Kaatsch P, Katalinic A, Garami M, Jakab Z, Comber H, Mazzoleni G, Bulatko A, Buzzoni C, Giacomin A, Sutera Sardo A, Mancuso P, Ferretti S, Barchielli A, Caldarella A, Gatta G, Sant M, Amash H, Amati C, Baili P, Berrino F, Bonfarnuzzo S, Botta L, Capocaccia R, Di Salvo F, Foschi R, Margutti C, Meneghini E, Minicozzi P, Trama A, Serraino D, Zucchetto A, De Angelis R, Caldora M, Carrani E, Francisci S, Mallone S, Pierannunzio D, Roazzi P, Rossi S, Santaquilani M, Tavilla A, Pannozzo F, Busco S, Filiberti R, Marani E, Ricci P, Pascucci C, Autelitano M, Spagnoli G, Cirilli C, Fusco M, Vitale M, Usala M, Vitale F, Ravazzolo B, Michiara M, Merletti F, Maule M, Tumino R, Mangone L, Di Felice E, Falcini F, Iannelli A, Sechi O, Cesaraccio R, Piffer S, Madeddu A, Tisano F, Maspero S, Fanetti A, Candela P, Scuderi T, Stracci F, Bianconi F, Tagliabue G, Contiero P, Rugge M, Guzzinati S, Pildava S, Smailyte G, Calleja N, Agius D, Johannesen T, Rachtan J, Góźdź S, Mężyk R, Błaszczyk J, Bębenek M, Bielska-Lasota M, Forjaz de Lacerda G, Bento M, Castro C, Miranda A, Mayer-da-Silva A, Safaei Diba C, Primic-Zakelj M, Errezola M, Bidaurrazaga J, Vicente Raneda M, Díaz García J, Marcos-Navarro A, Marcos-Gragera R, Izquierdo Font A, Sanchez M, Chang D, Navarro C, Chirlaque M, Moreno-Iribas C, Ardanaz E, Peris-Bonet R, Pardo Romaguera E, Galceran J, Carulla M, Lambe M, Mousavi M, Bouchardy C, Usel M, Ess S, Frick H, Lorez M, Herrmann C, Bordoni A, Spitale A, Konzelmann I, Visser O, Aarts M, Otter R, Coleman M, Allemani C, Rachet B, Verne J, Stiller C, Gavin A, Donnelly C, Brewster D. Geographical variability in survival of European children with central nervous system tumours. Eur J Cancer 2017; 82:137-148. [DOI: 10.1016/j.ejca.2017.05.028] [Show More Authors] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2017] [Revised: 05/11/2017] [Accepted: 05/16/2017] [Indexed: 11/28/2022]
|